Study Drug: Experimental drug that slows blood clotting, an inhibitor of clotting factor XI. A low dose of this experimental drug is expected to prevent the reformation of clots at the site of previous blood vessel blockage.
Main Inclusion Criteria: Patients who have had a heart attack in the last 7 days.
Start of patient enrollment: January 2024
Planned completion of new patient enrollment: October 2024
Testimonials from
our patients
“Izuzetno sam zadovoljna interakcijom – mogu saznati sve o bolesti i liječenju.”
“Prijava putem upitnika na web stranici je veoma jednostavna.”
“Uključivanje u naše studije je jednostavno i intuitivno.”
